Clinical Research Directory

Inclusion Criteria: * Eight years or older with HNC diagnosis confirmed histologically o Stage 1-3 HNC pathologically confirmed diagnosis of squamous cell carcinoma of the oropharynx, larynx, hypopharynx, nasopharyngeal, or oral cavity * Plan to receive radiotherapy (\>60 Gy), chemo-irradiation or bio-radiation either as primary or as a post-operative treatment to the head and neck region * Eastern Cooperative Oncology Group Performance Status (ECOGPS) performance status 0 or 1 * Comply with the study protocol * Capable of signing a written informed consent Exclusion Criteria: * An allergy, intolerance, or contraindication to colchicine * Current treatment with colchicine for medical conditions, e.g. gout and Familial Mediterranean Fever (FMF) * Estimated glomerular filtration rate (GFR) \< 55 ml/min since colchicine should not be given * Severe liver disease or current aminotransferase levels of more than 1.5 times the upper limit of the normal range * Previous irradiation to the head and/or neck region * Distant metastatic disease or locally recurrent disease * Pre-existing skin rashes, ulcerations, or open wounds in the treatment area * Known allergic and other systemic skin diseases even when not directly affecting irradiated fields * Substance abuse, medical conditions, and/or social issues that would limit conduct or follow-up in the research study, in the opinion of the investigator * Any condition that is unstable or could affect the safety of the patient and their compliance in the study as judged by the investigator * Using high doses of non-steroidal anti-inflammatory drugs * Pregnant and lactating women * Psychiatric illness that would prevent the patient from giving informed consent * Taking cetuximab or other radiosensitizing agents.